Category: Pharma Trends
-

Roche’s Divarasib Improves Survival in Phase 3 KRAS G12C Lung Cancer Trial
Roche’s divarasib improved median overall survival to 17.7 months versus 12.0 months with sotorasib or adagrasib in Phase 3 Krascendo 1. The findings inform treatment choice in KRAS G12C-mutated lung cancer but do not establish efficacy after KRAS-inhibitor resistance.
-

Moderna and Merck’s Phase 3 Cancer Vaccine: The Added Benefit
Moderna and Merck’s Phase 3 melanoma results show a 12.2-percentage-point improvement in estimated two-year recurrence-free survival with intismeran plus Keytruda. This analysis examines the added benefit, treatment burden, and why overall survival remains an open question.
-

AstraZeneca’s Ultomiris Wins FDA Accelerated Approval for IgA Nephropathy
AstraZeneca’s Ultomiris won FDA accelerated approval to reduce proteinuria in adults with primary IgA nephropathy. Phase 3 results support C5 inhibition, while long-term kidney-function benefit remains unconfirmed.
-

GSK’s Hibsago Wins FDA Approval for Chronic Hepatitis B
GSK’s Hibsago (bepirovirsen) won FDA approval for selected adults with chronic hepatitis B. Explore its 19% functional cure result, RNA-targeting mechanism, treatment requirements and key safety risks.
-

Viatris and Opus’ Ryzumvi Wins FDA Approval for Adult Presbyopia
Ryzumvi wins FDA approval for adult presbyopia. Explore its pupil-reducing mechanism, Phase 3 results and the commercial challenges facing Viatris and Opus Genetics.
-

Roche’s Enspryng Wins FDA Approval for Thyroid Eye Disease
Roche’s Enspryng wins FDA approval for adult thyroid eye disease. Explore its IL-6 receptor blockade, antibody recycling technology, mixed Phase 3 results and the commercial implications of at-home treatment.
-

ImmunityBio’s Anktiva Wins FDA Expansion in Bladder Cancer
The FDA expanded ImmunityBio’s Anktiva plus BCG to high-grade papillary-only bladder cancer. The decision extends existing CIS efficacy evidence to a related patient population, broadening the IL-15 receptor agonist’s approved role.
-

BMS’ RYZ101 Meets Phase 3 Endpoint in Neuroendocrine Tumors
BMS’ RYZ101 met its Phase 3 progression-free survival endpoint in neuroendocrine tumors after lutetium-177 therapy. Detailed efficacy and safety data remain pending.
-

Teva’s Weltruza Wins FDA Approval for Monthly Schizophrenia Treatment
Teva’s Weltruza wins FDA approval for monthly schizophrenia treatment. Medincell’s delivery technology reduces administration burden, while olanzapine’s metabolic risks remain.
